Pharmacokinetics of Clindamycin in Obese and Nonobese Children.

Journal Article (Clinical Trial;Journal Article)

Although obesity is prevalent among children in the United States, pharmacokinetic (PK) data for obese children are limited. Clindamycin is a commonly used antibiotic that may require dose adjustment in obese children due to its lipophilic properties. We performed a clindamycin population PK analysis using data from three separate trials. A total of 420 samples from 220 children, 76 of whom had a body mass index greater than or equal to the 95th percentile for age, were included in the analysis. Compared to other metrics, total body weight (TBW) was the most robust measure of body size. The final model included TBW and a sigmoidal maturation relationship between postmenstrual age (PMA) and clearance (CL): CL (liters/hour) = 13.8 × (TBW/70)0.75 × [PMA2.83/(39.52.83+PMA2.83)]; volume of distribution (V) was associated with TBW, albumin (ALB), and alpha-1 acid glycoprotein (AAG): V (liters) = 63.6 × (TBW/70) × (ALB/3.3)-0.83 × (AAG/2.4)-0.25 After accounting for differences in TBW, obesity status did not explain additional interindividual variability in model parameters. Our findings support TBW-based dosing for obese and nonobese children.

Full Text

Duke Authors

Cited Authors

  • Smith, MJ; Gonzalez, D; Goldman, JL; Yogev, R; Sullivan, JE; Reed, MD; Anand, R; Martz, K; Berezny, K; Benjamin, DK; Smith, PB; Cohen-Wolkowiez, M; Watt, K; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee,

Published Date

  • April 2017

Published In

Volume / Issue

  • 61 / 4

PubMed ID

  • 28137820

Pubmed Central ID

  • PMC5365720

Electronic International Standard Serial Number (EISSN)

  • 1098-6596

Digital Object Identifier (DOI)

  • 10.1128/AAC.02014-16


  • eng

Conference Location

  • United States